Unnamed: 0,title,date,stock,sentiment
1041944.0,"Palatin Technologies Q3 EPS $(0.020), Inline",2020-05-12 07:31:00-04:00,PTN,neutral
1041945.0,"Palatin Technologies, Inc. Announces First Patient Enrolled In Dry Eye Disease Phase 2 Clinical Trial With PL9643",2020-02-19 07:33:00-05:00,PTN,neutral
1041946.0,"Palatin Technologies Q2 EPS $(0.02) Misses $(0.01) Estimate, Sales $20.61K Does Not Compare To $2.48M Estimate",2020-02-11 07:36:00-05:00,PTN,negative
1041947.0,Palatin Provides Corporate Update And 2020 Calendar Outlook,2020-01-21 07:34:00-05:00,PTN,neutral
1041948.0,"Palatin Technologies Q1 EPS $(0.02), Inline",2019-11-13 07:30:00-05:00,PTN,neutral
1041949.0,"Palatin Technologies Q4 EPS $0.23 Up From $0.06 YoY, Sales $20.6M, Same YoY",2019-09-12 07:37:00-04:00,PTN,neutral
1041950.0,"Earnings Scheduled For September 12, 2019",2019-09-12 04:05:00-04:00,PTN,neutral
1041951.0,"A Look At Benzinga Pro's Most-Searched Tickers For June 25, 2019",2019-06-25 12:07:00-04:00,PTN,neutral
1041952.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, June 25 2019",2019-06-25 10:26:00-04:00,PTN,positive
1041953.0,60 Biggest Movers From Yesterday,2019-06-25 05:12:00-04:00,PTN,neutral
1041954.0,40 Stocks Moving In Monday's Mid-Day Session,2019-06-24 12:35:00-04:00,PTN,neutral
1041955.0,"5 Stocks To Watch For June 24, 2019",2019-06-24 04:23:00-04:00,PTN,neutral
1041956.0,"Palatin Technolog Shares Rise 52% Premarket; On Friday, FDA Approved NDA for Vyleesi for Treatment of Premenopausal Women with Acquired HSDD",2019-06-24 04:09:00-04:00,PTN,positive
1041957.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-06-22 15:07:00-04:00,PTN,neutral
1041958.0,Palatin Technologies Reports Granted FDA Orphan Drug Designation For PL-8177 For Treatment Of Non-Infectious Uveitis,2019-06-06 07:31:00-04:00,PTN,positive
1041959.0,Palatin Technologies shares are trading higher after reports surfaced that the company won Orphan Drug Designation from the FDA for its Anterior Uveitis Treatment.,2019-06-04 16:26:00-04:00,PTN,positive
1041960.0,Palatin Therapeutics Shares Up 10.5% After Hours As Hearing Co. Won Orphan Drug Designation From FDA For Its Anterior Uveitis Treatment,2019-06-04 16:11:00-04:00,PTN,positive
1041961.0,"Palatin Technologies Q3 EPS $(0.03), Inline",2019-05-09 07:58:00-04:00,PTN,neutral
1041962.0,52 Biggest Movers From Yesterday,2019-04-05 05:55:00-04:00,PTN,neutral
1041963.0,44 Stocks Moving In Thursday's Mid-Day Session,2019-04-04 12:39:00-04:00,PTN,neutral
1041964.0,32 Stocks Moving In Thursday's Pre-Market Session,2019-04-04 08:18:00-04:00,PTN,neutral
1041965.0,"Palatin Technologies Reports Top-Line Results Of PL-8177 Study For Ulcerative Colitis, Other Inflammatory Bowel Diseases: Study Met All Primary, Secondary Endpoints",2019-04-04 07:41:00-04:00,PTN,neutral
1041966.0,Palatin Technologies Q2 EPS $(0.02) Beats $(0.03) Estimate,2019-02-12 07:34:00-05:00,PTN,neutral
1041967.0,Palatin Technologies Says the FDA Has Extended the Prescription Drug User Fee Act Date for Vyleesi,2019-01-07 07:57:00-05:00,PTN,neutral
1041968.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,PTN,neutral
1041969.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,PTN,neutral
1041970.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,PTN,negative
1041971.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:26:00-05:00,PTN,negative
1041972.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018",2018-11-20 09:12:00-05:00,PTN,negative
1041973.0,"Palatin Technologies, Inc. Q1 EPS $(0.03) Down From $0.05 YoY, Sales $34.505K Miss $1.32M Estimate",2018-11-13 07:36:00-05:00,PTN,negative
1041974.0,Palatin Technologies Reports First-In-Human Study Results Of Subcutaneous Administration Of PL-8177,2018-11-08 07:43:00-05:00,PTN,neutral
1041975.0,Seeing Sharp Spike In Palatin Technologies Following Bullish Blog Post Concerning One Of The Company's Drugs,2018-10-25 13:21:00-04:00,PTN,neutral
1041976.0,"Palatin Technologies Q4 EPS $0.06 Down From $0.07 YoY, Sales $20.6M Beat $8.68M Estimate",2018-09-13 07:33:00-04:00,PTN,neutral
1041977.0,"Earnings Scheduled For September 13, 2018",2018-09-13 04:44:00-04:00,PTN,neutral
1041978.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs",2018-09-09 16:46:00-04:00,PTN,neutral
1041979.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2018-09-02 09:41:00-04:00,PTN,neutral
1041980.0,"Benzinga's Top Upgrades, Downgrades For June 27, 2018",2018-06-27 10:14:00-04:00,PTN,positive
1041981.0,"Ladenburg Thalmann Initiates Coverage On Palatin Technologies, Inc. Common Stock with Buy Rating, Announces $3 Price Target",2018-06-27 07:38:00-04:00,PTN,neutral
1041982.0,"Palatin Technologies Shares Fall Sharply Over Last Min., Now Down 10.2% For Session; Stock Rebounded At Exactly $1 Level; Not Seeing Near-Term News To Justify Move Lower",2018-06-08 15:21:00-04:00,PTN,neutral
1041983.0,Palatin Technologies Announces FDA Acceptance to Review its NDA for Bremelanotide,2018-06-04 07:11:00-04:00,PTN,positive
1041984.0,"Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway",2018-05-15 08:44:00-04:00,PTN,positive
1041985.0,Palatin Technologies Q3 Made $8.963M Sales,2018-05-15 07:32:00-04:00,PTN,neutral
1041986.0,HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold,2018-04-06 14:43:00-04:00,PTN,neutral
1041987.0,Palatin Technologies Shares Up 5.8% After H.C. Wainwright Earlier Initiated Stock With Buy Rating And $5 Price Target,2018-04-06 12:22:00-04:00,PTN,positive
1041988.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-06 09:29:00-04:00,PTN,neutral
1041989.0,"Benzinga's Top Upgrades, Downgrades For April 6, 2018",2018-04-06 09:12:00-04:00,PTN,positive
1041990.0,"H.C. Wainwright Initiates Coverage On Palatin Technologies, Inc. Common Stock with Buy Rating, Announces $5.00 Price Target",2018-04-06 07:02:00-04:00,PTN,neutral
1041991.0,Palatin Technologies Submits an NDA for Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women,2018-03-26 08:01:00-04:00,PTN,neutral
1041992.0,"Palatin Technologies Reports Q2 EPS $0.01 vs $0.00 Est., Sales $10.6M",2018-02-12 07:35:00-05:00,PTN,neutral
1041993.0,"Palatin Technologies, Inc. Begins Subject Dosing in First-in-Human Clinical Study of PL-8177",2018-02-05 07:30:00-05:00,PTN,neutral
1041994.0,Palatin Technologies Announces FDA Clearance of Investigational New Drug Application for PL-8177 For Ulcerative Colitis,2018-01-03 07:30:00-05:00,PTN,neutral
1041995.0,"UPDATE: Palatin Technologies Will Receive $500K Upfront Payment From Kwangdong Pharma, Eligible For Up To $3M In First Commercial Sale in Korea, Up to $37.5M In Sales Related Milestones Plus Royalties On Net Sales",2017-11-21 07:38:00-05:00,PTN,neutral
1041996.0,Palatin Technologies Reports Signing Of Licensing Deal With Kwangdong Pharma For Republic Of Korea,2017-11-21 07:37:00-05:00,PTN,neutral
1041997.0,"13F Filing From Baker Bros Shows New Stake In GW Pharmaceuticals, Slight Increase To Ignyta Stake, Exited Stake In Palatin Technologies and Zogenix",2017-11-14 16:01:00-05:00,PTN,positive
1041998.0,"Palatin Technologies Reports Q1 EPS $0.05, Sales $26.94M vs $23.50M Est.",2017-11-13 07:34:00-05:00,PTN,neutral
1041999.0,"Earnings Scheduled For November 13, 2017",2017-11-13 03:15:00-05:00,PTN,neutral
1042000.0,"Palatin Technologies FY 2017 EPS $(0.07) vs $(0.33) Est., Sales $44.72M vs $20.11M Est.",2017-09-25 07:32:00-04:00,PTN,neutral
1042001.0,"Earnings Scheduled For September 22, 2017",2017-09-25 05:08:00-04:00,PTN,neutral
1042002.0,15 Biggest Mid-Day Gainers For Wednesday,2017-09-06 12:43:00-04:00,PTN,neutral
1042003.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-09-06 08:06:00-04:00,PTN,neutral
1042004.0,"Palatin Technologies Announces Licensing Agreement with Fosun Pharma, Palatin to Receive an Upfront $5M Payment",2017-09-06 07:36:00-04:00,PTN,positive
1042005.0,"Palatin Technologies Q3 EPS $(0.02) vs $(0.08) YoY, Sales $10.82M",2017-05-16 07:39:00-04:00,PTN,neutral
1042006.0,"Earnings Scheduled For May 16, 2017",2017-05-16 04:47:00-04:00,PTN,neutral
1042007.0,"Palatin Technologies Reports Q2 EPS $(0.06) vs $(0.07) in Same Qtr. Last Year, Sales $403M",2017-02-09 07:39:00-05:00,PTN,neutral
1042008.0,Palatin Tech Licenses Right to Develop Rekynda to AMAG Pharma for Initial Payment of $60M,2017-02-03 07:13:00-05:00,PTN,neutral
1042009.0,Mid-Afternoon Market Update: Ariad Pharmaceuticals Surges On Acquisition News; Stage Stores Shares Slide,2017-01-09 15:14:00-05:00,PTN,positive
1042010.0,AMAG Pharmaceuticals Tanks After Raymond James Downgrade,2017-01-09 11:45:00-05:00,PTN,neutral
1042011.0,"UPDATE: AMAG Pharmaceuticals, Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm",2017-01-09 08:28:00-05:00,PTN,positive
1042012.0,12 Biggest Mid-Day Losers For Thursday,2016-12-01 13:09:00-05:00,PTN,negative
1042013.0,22 Stocks Moving In Thursday's Pre-Market Session,2016-12-01 08:30:00-05:00,PTN,neutral
1042014.0,Palatin Technologies Prices 25.38M Shares For $16.5M In Gross Proceeds,2016-12-01 08:23:00-05:00,PTN,negative
1042015.0,Palatin Technologies Announces Offering Of Common Stock And Warrants,2016-11-30 16:36:00-05:00,PTN,neutral
1042016.0,Palatin Technologies Reprots Q1 EP S$(0.08) vs. Est. $(0.08),2016-11-15 07:33:00-05:00,PTN,neutral
1042017.0,"Palatin's Female Arousal Drug Data Impresses, Investors React Positively",2016-11-03 09:06:00-04:00,PTN,positive
1042018.0,"Noble Financial Maintains Buy On Palatin Technologies, Believes Positive BMT Result Could Garner Interest For A Partnership, Maintains $4 PT",2016-11-02 13:59:00-04:00,PTN,positive
1042019.0,TheStreet's Adam Feuerstein Recently Publishes Series of Tweets Downplaying/Throwing Cold Water on Reuters Report of Palatin Takeover Offer,2016-11-02 10:12:00-04:00,PTN,neutral
1042020.0,Palatin Technologies Explores Potential Sale  -Reuters,2016-11-02 10:10:00-04:00,PTN,neutral
1042021.0,Palatin Technologies Spikes 1117% After Hours to $1.09 as Female Sexual Desire Drug Bremelanotide Meets Goals Of Phase III Trials,2016-11-01 16:26:00-04:00,PTN,positive
1042022.0,Palatin Technologies Reports Q4 EPS $(0.09) vs. Est. $(0.06),2016-09-20 07:31:00-04:00,PTN,neutral
1042023.0,"Earnings Scheduled For September 20, 2016",2016-09-20 04:03:00-04:00,PTN,neutral
1042024.0,Palatin Technologies Reports Received Patent Strengthening Its Melanocortin Peptide IP,2016-06-06 07:32:00-04:00,PTN,positive
1042025.0,Palatin Technologies Reports Received Patent Strengthening Melanocortin Peptide IP,2016-05-26 07:35:00-04:00,PTN,positive
1042026.0,Palatin Technologies Reports Q3 EPS $(0.08) vs. Est. $(0.08),2016-05-17 07:32:00-04:00,PTN,neutral
1042027.0,"Earnings Scheduled For May 17, 2016",2016-05-17 04:05:00-04:00,PTN,neutral
1042028.0,Palatin Technologies Reports Q2 EPS $(0.08) vs $(0.07) Est.,2016-02-16 07:37:00-05:00,PTN,neutral
1042029.0,7 Biotech Traders Pick Their Favorite Stocks For 2016,2016-01-28 16:53:00-05:00,PTN,positive
1042030.0,Palatin Technologies Hits Target Patient Enrollment in Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction,2015-12-10 07:32:00-05:00,PTN,negative
1042031.0,"Palatin Tech Reports Q1 EPS $(0.08), Inline",2015-11-12 07:32:00-05:00,PTN,neutral
1042032.0,Palatin Tech Reports Q4 Loss of $0.09/Share vs Loss of $0.06/Share Est.,2015-09-21 07:31:00-04:00,PTN,negative
1042033.0,"Palatin Technologies, Richter Terminate Bremelanotide License Agreement For Female Sexual Dysfunction",2015-09-21 07:02:00-04:00,PTN,positive
1042034.0,"Earnings Scheduled For September 21, 2015",2015-09-21 04:01:00-04:00,PTN,neutral
1042035.0,Palatin Technologies Shares +39% Premarket Following Wall Street Journal Report Valeant Could Acquire Sprout Pharmaceuticals for $1B,2015-08-20 05:23:00-04:00,PTN,positive
1042036.0,"Valeant Pharmaceuticals Near $1B Acquisition of Sprout Pharmaceuticals, According to Source -Wall Street Journal",2015-08-20 04:36:00-04:00,PTN,neutral
1042037.0,Palatin Technologies +45% Premarket Following Announcement of FDA Approval of Sprout Pharmaceuticals' Treatment for Sexual Dysfunction Flibanserin,2015-08-19 05:22:00-04:00,PTN,positive
1042038.0,Palatin Technologies Supports FDA's Approval of the First-Ever Treatment for Female Sexual Dysfunction,2015-08-18 20:51:00-04:00,PTN,positive
1042039.0,Palatin Shares Rise 30% After-Hours as FDA Approves Sprout Pharmaceuticals' Flibanserin,2015-08-18 18:57:00-04:00,PTN,positive
1042040.0,"FDA Approves Addyi, First Treatment for Sexual Desire Disorder, to Treat Premenopausal Women",2015-08-18 18:49:00-04:00,PTN,positive
1042041.0,Morgan Stanley Calls Bottom In Oil Services,2015-07-09 14:45:00-04:00,PTN,neutral
1042042.0,Palatin Technologies Announces Closing of $30M Private Placement,2015-07-06 07:30:00-04:00,PTN,neutral
1042043.0,"Worst Performing Industries For June 16, 2015",2015-06-16 11:36:00-04:00,PTN,negative
1042044.0,"Palatin Technologies Continues To Post Gains, Up ~17% Monday, As Women's Viagara (Bremelanotide) Receives Marketing License",2015-06-08 10:36:00-04:00,PTN,positive
1042045.0,Why Palatin Is Still A Buy,2015-06-07 17:46:00-04:00,PTN,neutral
1042046.0,"Roth Capital: Palatin Technologies Still A Buy, Worth $4/Share",2015-06-05 10:50:00-04:00,PTN,positive
1042047.0,Morning Market Gainers,2015-06-05 09:42:00-04:00,PTN,neutral
1042048.0,Benzinga's Top #PreMarket Gainers,2015-06-05 08:09:00-04:00,PTN,positive
1042050.0,Palatin Backs FDA Advisory Committee's Recommendation To Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder In Women,2015-06-04 17:36:00-04:00,PTN,negative
1042051.0,Palatin Tech Reports Q3 Loss of $0.07/Share vs Loss of $0.06/Share Est.,2015-05-13 07:33:00-04:00,PTN,negative
1042052.0,"Canaccord Genuity Initiates Coverage on Palatin Technologies at Buy, Announces $4.00 PT",2015-03-02 07:27:00-05:00,PTN,neutral
1042053.0,"Paltin Tech Reports Q2 EPS 0.03 Vs Est $0.01, Revs $8.02M Vs Est $54.41M",2015-02-13 07:35:00-05:00,PTN,neutral
1042054.0,"Earnings Scheduled For February 13, 2015",2015-02-13 05:09:00-05:00,PTN,neutral
1042055.0,Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction,2014-12-29 07:31:00-05:00,PTN,negative
1042056.0,"Earnings Scheduled For November 18, 2014",2014-11-18 05:24:00-05:00,PTN,neutral
1042057.0,S-1 from Palatin Technologies Shows Registration to Sell Up to $57.5M in Shares,2014-09-29 09:21:00-04:00,PTN,positive
1042058.0,"Palatin Technologies, Inc. Reports Q4 EPS of $(0.04) vs $0.03 Est",2014-09-09 07:32:00-04:00,PTN,neutral
1042059.0,"Earnings Scheduled For September 9, 2014",2014-09-09 05:24:00-04:00,PTN,neutral
1042060.0,Palatin Technologies Announces Notification of Patent Allowance on Melanocortin Receptor-1 Specific Peptides,2014-07-09 07:30:00-04:00,PTN,neutral
1042061.0,"Palatin Technologies, Inc. Reports Q3 EPS of $(0.01) vs $(0.03) Est",2014-05-13 07:30:00-04:00,PTN,neutral
1042062.0,UPDATE: Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder,2014-02-24 07:36:00-05:00,PTN,positive
1042063.0,Palati Tech Reports New Data Shows Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder,2014-02-24 07:35:00-05:00,PTN,neutral
1042064.0,"Palatin Technologies, Inc. Reports Q2 EPS of $(0.03) vs $0.03 Est",2014-02-18 07:32:00-05:00,PTN,neutral
1042065.0,Palatin Technologies Receives $1.85M from Sale of New Jersey Tax Credits ,2014-01-23 09:19:00-05:00,PTN,positive
1042066.0,Palatin Technologies Contacted by NYSE Regarding Market Activity ,2014-01-13 16:32:00-05:00,PTN,neutral
1042067.0,"Palatin Technologies, Inc. Reports Q4 EPS of $(0.04) vs $(0.05) Est",2013-09-30 17:20:00-04:00,PTN,neutral
1042068.0,"Earnings Scheduled For September 30, 2013",2013-09-30 05:32:00-04:00,PTN,neutral
1042069.0,UPDATE: Piper Jaffray Initiates Palatin Technologies at Overweight Following End of BMT Testing,2013-06-21 08:17:00-04:00,PTN,negative
1042070.0,"Piper Jaffray Initiates Coverage on Palatin Technologies, Inc. at Overweight, Announces $2.00 PT",2013-06-20 16:10:00-04:00,PTN,negative
1042071.0,"Palatin Technologies, Inc. Reports Q3 EPS of $(0.04) vs $(0.06) Est",2013-05-14 07:45:00-04:00,PTN,neutral
1042072.0,"Earnings Scheduled For May 14, 2013 ",2013-05-14 05:02:00-04:00,PTN,neutral
1042073.0,"Palatin Tech Announces USPTO Issued Notice of Allowance for Patent App 13/472,914",2013-03-19 07:32:00-04:00,PTN,neutral
1042074.0,A Peek Into The Market Before The Trading Starts,2013-03-01 07:15:00-05:00,PTN,neutral
1042075.0,Palatin Technologies Announces Positive Data for Bremelanotide in Female Sexual Dysfunction ,2013-03-01 07:05:00-05:00,PTN,positive
1042076.0,"Palatin Technologies, Inc. Reports Q2 EPS of $(0.02) vs $0.01 Est",2013-02-14 07:34:00-05:00,PTN,neutral
1042077.0,Palatin Technologies Reports Q1 EPS $-0.15 vs $-0.16 Est,2012-11-14 07:33:00-05:00,PTN,neutral
1042078.0,"Benzinga's Microcap Movers for Thursday November 8, 2012",2012-11-08 22:06:00-05:00,PTN,neutral
1042079.0,Palatin Technologies Reports Positive Phase 2B  Results for Bremelanotide in Female Sexual Dysfunction Trial ,2012-11-08 08:22:00-05:00,PTN,positive
1042080.0,"Earnings Scheduled For September 11, 2012",2012-09-11 00:16:00-04:00,PTN,neutral
1042081.0,"Benzinga's Microcap Movers for Friday July 6, 2012",2012-07-06 16:54:00-04:00,PTN,neutral
1042082.0,Palatin Technologies Announces Pricing of $35 Million Private Placement of Common Stock and Warrants ,2012-07-02 16:31:00-04:00,PTN,neutral
1042083.0,Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration ,2012-06-19 07:33:00-04:00,PTN,neutral
1042084.0,Palatin Technologies Announces First Patient Dosed in Second Phase I Clinical Trial of Obesity Compound from Research Collaboration  ,2012-04-19 07:32:00-04:00,PTN,neutral
1042085.0,Palatin Technologies Completes Enrollment in Phase 2B Bremelanotide Female Sexual Dysfunction Trial,2012-03-08 07:31:00-05:00,PTN,negative
1042086.0,Palatin Technologies Receives $1.1M From Sale of New Jersey State Tax Credits ,2012-01-17 07:31:00-05:00,PTN,positive
1042087.0,Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca ,2011-08-04 07:58:00-04:00,PTN,neutral
1042088.0,"Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction ",2011-06-28 07:31:00-04:00,PTN,negative
1042089.0,Palatin Technologies Issued U.S. Patent for Key Component in PL-3994 Drug Candidate ,2011-06-21 07:34:00-04:00,PTN,neutral
1042090.0,"Palatin Technologies CEO Buys 50,000 Shares of PTN",2011-03-03 16:45:00-05:00,PTN,positive
1042091.0,FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma ,2011-03-03 07:30:00-05:00,PTN,positive
1042092.0,"Palatin Technologies, Inc. Announces Proposed Offering of Common Stock and Warrants ",2011-02-23 16:59:00-05:00,PTN,neutral
1042093.0,"Palatin Technologies, Inc. Reports Q2 EPS of $(0.09) ",2011-02-15 07:34:00-05:00,PTN,neutral
1042094.0,Palatin Technologies Receives Non-Compliance Letter from NYSE Amex,2010-12-02 16:04:00-05:00,PTN,neutral
1042095.0,"Palatin Technologies, Inc. Reports First Quarter 2011 EPS of $(0.39)",2010-11-15 16:32:00-05:00,PTN,neutral
1042096.0,Palatin Announces Strategic Realignment of Operations  ,2010-09-24 16:17:00-04:00,PTN,neutral
1042097.0,"Top 5 Stocks In The Healthcare Sector With Highest ROE (VRX, TLCR, HLF, USNA, PTN)",2010-04-19 07:30:00-04:00,PTN,positive
1042098.0,"Today's Morning Top Gainers (CHTP,XRTX,PTN,XJT,ATV)",2009-10-01 11:37:00-04:00,PTN,positive
